New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:07 EDTBMY, CLDXCelldex to collaborate with Bristol-Myers on varlilumab/nivolumab combo therapy
Bristol-Myers Squibb (BMY) and Celldex Therapeutics (CLDX) announced that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers' investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer, metastatic melanoma, ovarian, colorectal and squamous cell head and neck cancers. Under the terms of this agreement, Bristol-Myers Squibb will make a one-time payment of $5M to Celldex and the parties will share development costs. Celldex will be responsible for conducting the Ph 1/2 study, which is expected to begin in the fourth quarter of 2014. Additionally, the parties have re-structured an existing agreement between Celldex and Medarex related to Celldex’s CD27 program, and waived certain future milestone payments and reduced future royalty rates that would have been due from Celldex to Medarex. Medarex was acquired by Bristol-Myers Squibb in September of 2009. The companies will work exclusively with each other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. Bristol-Myers Squibb will have a time-limited right of first negotiation if Celldex wishes to out-license varlilumab.
News For CLDX;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:52 EDTBMYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:33 EDTBMYBristol-Myers receives positive CHMP opinion for Nivolumab
Subscribe for More Information
May 21, 2015
07:37 EDTBMYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:01 EDTBMYBristol-Myers receives amended breakthrough therapy designation for daclatasvir
Subscribe for More Information
07:21 EDTBMYUBS to hold a conference
Subscribe for More Information
May 19, 2015
08:57 EDTCLDX, BMYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:56 EDTBMYGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:45 EDTBMYJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
May 14, 2015
11:03 EDTBMYBristol-Myers treatment of progressive supranuclear palsy granted orphan status
Subscribe for More Information
10:41 EDTBMYAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:22 EDTBMYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:09 EDTBMYBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
May 13, 2015
17:28 EDTCLDXCelldex to present data from Phase 2 ReACT study of Rintega at ASCO
Celldex Therapeutics announced that several clinical programs, including the Phase 2 ReACT study of Rintega in patients with recurrent glioblastoma, or GBM, will be presented at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago. The ReACT presentation will include final analysis of progression-free survival at 6 months, or PFS6, and current data on overall survival and other endpoints. Data contained in the published abstract were from an analysis in October 2014. Data to be presented in the oral session will include comprehensive data from the study through March.
13:12 EDTBMYSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use